Early Pre-Pilot Study Advances Potassium Biosensor
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Archer Materials Limited reports on an early-stage blood collection study for its potassium Biosensor, highlighting its significance in developing an integrated testing system. The study involved evaluating different blood collection methods to minimize haemolysis, which can affect potassium measurement accuracy. Results indicate a promising capillary collection method that produced low haemolysis levels, comparable to conventional methods, aiding future prototype development. The findings will inform the design of upcoming pilot studies and regulatory submissions, including to the FDA.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Archer Materials Limited on 6ix
Earlier from Archer Materials
- Application for quotation of securities - AXE
- Results of Share Purchase Plan
- Biochip Advances Towards Clinical-Ready Device Development
- Archer Materials investor webinar on the IonQ partnership and Share Purchase Plan
- Archer Completes $7m Placement and Launches SPP Offer
Later from Archer Materials
- Results of General Meeting
- 2026 Corporate Governance Statement and Appendix 4G
- Appendix 4E and 2026 Annual Report
- Prospectus
- Notification regarding unquoted securities - AXE
Follow Archer Materials into a list and get an email when it puts out news.
Follow Archer Materials